A Phase 1 interventional study of Nipocalimab and Etanercept in Healthy, sponsored by Janssen Research & Development, LLC. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-04.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary purpose of this study is to assess the effect of nipocalimab on the pharmacokinetic (PK) of etanercept (Part 1); and to assess the effect of hydroxychloroquine (HCQ) on total serum immunoglobin G (IgG) reduction by nipocalimab (Part 2) in healthy participants.
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single subcutaneous (SC) dose of etanercept on Day 1 in Period 1 followed by single intravenous (IV) infusion of nipocalimab on Day 29, SC administration of etanercept followed by an IV infusion of nipocalimab on Day 43 and then a single dose of nipocalimab IV infusion on Day 57 in Period 2 of Part 1. There will be a wash-out period of 28 days between Day 1 of Period 1 and Day 29 of Period 2 in Part 1.
Drug: Nipocalimab · Drug: Etanercept
Participants will receive a single IV infusion of nipocalimab on Day 1 in Cohort 1 of Part 2.
Drug: Nipocalimab
Participants will receive a single oral dose of HCQ film-coated tablets once daily from Day 1 to Day 22 and a single IV infusion of nipocalimab on Day 8 in Cohort 2 of Part 2.
Drug: Nipocalimab · Drug: Hydroxychloroquine
Nipocalimab will be administered as an IV infusion.
Also known as: JNJ-80202135, M281
Etanercept will be administered subcutaneously.
HCQ will be administered orally.
Part 1: Serum Etanercept Concentration
Serum etanercept concentration will be reported.
Time frame: Up to Day 99
Part 1: Ratio of Area Under the Concentration-time Curve (AUCR) of Etanercept
AUCR is defined as the ratio of area under the concentration-time curve.
Time frame: Up to Day 99
Part 1: Area Under the Concentration-time Curve of Etanercept from Time Zero to Time of Last Observed Quantifiable Concentration (AUC [0-Last])
AUC (0-last) is defined as area under the concentration-time curve of etanercept from time zero to time of last observed quantifiable concentration.
Time frame: Up to Day 99
Part 1: Area Under the Concentration-time Curve of Etanercept from Time Zero to Infinite time (AUC [0-Infinity])
AUC (0-Infinity) is defined as area under the concentration-time curve of etanercept from time zero to infinite time, calculated as the sum of AUC (0-last) and C(last)/lambda(z) where AUC (0-last) is area under the concentration-time curve of etanercept from time zero to time of last observed quantifiable concentration and C(last) is the last observed quantifiable concentration, and lambda(z) is apparent terminal elimination rate constant.
Time frame: Up to Day 99
Part 1: Maximum Observed Concentration (Cmax) of Etanercept
Cmax is defined as maximum observed concentration of etanercept.
Time frame: Up to Day 99
Part 1: Ratio of Maximum Observed Concentration (CmaxR) of Etanercept
CmaxR is defined as ratio of maximum observed concentration of etanercept.
Time frame: Up to Day 99
Part 1: Time to Reach the Last Observed Measurable Analyte Concentration (Tlast) of Etanercept
Tlast is defined as time to reach the last observed measurable analyte concentration of etanercept.
Time frame: Up to Day 99
Part 1: Time to Reach the Maximum Observed Concentration (Tmax) of Etanercept
Tmax is defined as time to reach the maximum observed concentration of etanercept.
Time frame: Up to Day 99
Part 1: Elimination Half-life (t1/2) of Etanercept
t1/2 is defined as elimination half-life associated with the terminal slope lambda(z) of the semilogarithmic drug concentration-time curve, calculated as 0.693/ lambda(z).
Time frame: Up to Day 99
Part 1: Total Apparent Clearance (CL/F) of Etanercept
CL/F is total apparent clearance of etanercept following subcutaneous (SC) administration, calculated as dose/AUC (0-infinity).
Time frame: Up to Day 99
Part 1: Apparent Volume of Distribution (Vdz/F) of Etanercept
Vdz/F is defined as apparent volume of distribution based on the terminal phase after an SC dose, calculated as dose/lambda(z)\*AUC(0-infinity).
Time frame: Up to Day 99
Part 2: Change from Baseline in Total Serum Immunoglobulin (Ig) Levels
Change from baseline in total serum Ig levels (serum IgG and IgG subtypes) through Day 50 will be reported.
Time frame: Baseline up to Day 50
Part 1: Number of Participants with Adverse Events (AEs)
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.
Time frame: Up to 4 months
Part 1: Number of Participants with Abnormalities in Physical Examinations
Number of participants with abnormalities in physical examinations (full and brief) will be reported. Full physical examinations will include a review of the following body systems: general appearance; thorough skin and oral mucosa evaluation; eyes, ears, nose, and throat; cardiovascular; respiratory; abdomen; peripheral pulsation; lymph nodes; neurologic; musculoskeletal; head, neck, and thyroid. A brief physical examination includes review of the following body systems: general appearance, thorough skin (including site of the injection) and oral mucosa, abdomen, respiratory, cardiovascular, any abnormalities noted on previous examinations.
Time frame: Up to 4 months
Part 1: Number of Participants with Abnormalities in Vital Sign Measurements
Number of participants with abnormalities in vital sign measurements (body temperature \[temporal artery measurement\], pulse/heart rate, respiratory rate, blood pressure) will be reported.
Time frame: Up to 4 months
Part 1: Number of Participants with Abnormalities in Clinical Laboratory Tests
Number of participants with abnormalities in clinical laboratory tests (serum chemistry, liver panel, hematology, and urinalysis) will be reported.
Time frame: Up to 4 months
Parts 1 and 2: Serum Nipocalimab Concentrations
Serum nipocalimab concentrations will be reported.
Time frame: Up to Day 99 (Part 1); up to Day 50 (Part 2)
Part 1: AUCR of Nipocalimab
AUCR is defined as the ratio of area under the concentration-time curve.
Time frame: Up to Day 99
Parts 1 and 2: AUC (0-Last) of Nipocalimab
AUC (0-last) is defined as area under the concentration-time curve of nipocalimab from time zero to time of last observed quantifiable concentration.
Time frame: Up to Day 99 (Part 1); up to Day 50 (Part 2)
Parts 1 and 2: AUC (0-Infinity) of Nipocalimab
AUC (0-Infinity) is defined as area under the concentration-time curve of nipocalimab from time zero to infinite time, calculated as the sum of AUC (0-last) and C(last)/lambda(z) where AUC (0-last) is area under the concentration-time curve of nipocalimab from time zero to time of last observed quantifiable concentration and C(last) is the last observed quantifiable concentration, and lambda(z) is apparent terminal elimination rate constant.
Time frame: Up to Day 99 (Part 1); up to Day 50 (Part 2)
Parts 1 and 2: Cmax of Nipocalimab
Cmax is defined as maximum observed concentration of nipocalimab.
Time frame: Up to Day 99 (Part 1); up to Day 50 (Part 2)
Part 1: CmaxR of Nipocalimab
CmaxR is defined as ratio of maximum observed concentration of nipocalimab.
Time frame: Up to Day 99
Parts 1 and 2: Tlast of Nipocalimab
Tlast is defined as time to reach the last observed measurable analyte concentration of nipocalimab.
Time frame: Up to Day 99 (Part 1); up to Day 50 (Part 2)
Parts 1 and 2: Tmax of Nipocalimab
Tmax is defined as time to reach the maximum observed concentration of nipocalimab.
Time frame: Up to Day 99 (Part 1); up to Day 50 (Part 2)
Parts 1 and 2: t1/2 of Nipocalimab
t1/2 is defined as elimination half-life associated with the terminal slope lambda(z) of the semilogarithmic drug concentration-time curve, calculated as 0.693/ lambda(z).
Time frame: Up to Day 99 (Part 1); up to Day 50 (Part 2)
Parts 1 and 2: Total Systemic Clearance of Nipocalimab (CL)
CL is defined as total systemic clearance of nipocalimab following an intravenous (IV) administration, calculated as dose/AUC (0-infinity).
Time frame: Up to Day 99 (Part 1); up to Day 50 (Part 2)
Parts 1 and 2: Volume of Distribution (Vdz) of Nipocalimab
Vdz is defined as volume of distribution, based on the terminal phase after an IV dose, calculated as dose/lambda(z)\*AUC (0-infinity).
Time frame: Up to Day 99 (Part 1); up to Day 50 (Part 2)
Part 1: Number of Participants with Antibodies to Nipocalimab
Number of participants with antibodies to nipocalimab will be reported.
Time frame: Up to Day 99
Part 2: Serum Lipid and Albumin Levels
Participants serum lipid and albumin levels will be reported.
Time frame: Up to Day 50
Part 2: Number of Participants with Receptor Occupancy (RO) Levels of Nipocalimab
Number of Participants with RO levels (example, neonatal Fc receptor \[FcRn\] RO in circulating monocytes) of nipocalimab will be reported.
Time frame: Up to Day 50
Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Data sharing details ↗ · www.janssen.com
No publications or documents are linked to this record.
Ran from Aug 2021 to primary completion in May 2022, 8 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nipocalimab · Etanercept · Hydroxychloroquine
Janssen Research & Development, LLC →